Trisura Group is a peppy, young specialty insurer with a pedigree

Trisura Group has grown to about 10 times its 2017 size, with book value per share rising from $4.59 at the end of 2017 to $19.42 at the end of last year and a 2025 combined ratio of 84.9%. The insurer expanded its U.S. footprint with the US$18 million acquisition of First Founders Assurance Co., giving it licensing in all 50 states. Management says the company still has a long runway for profitable growth, though the stock remains a roughly $2 billion small cap.

Analysis

TSU.TO is still being priced like a scaled-up niche insurer, but the more important setup is operating leverage in a fragmented specialty market. If management can keep loss discipline intact while writing more U.S. business, incremental premium growth should drop disproportionately to book value, which is the compounding engine here; that makes the stock more sensitive to underwriting slippage than to headline growth. The market is likely underestimating how much of the value creation path now depends on maintaining scarcity value in lines where larger carriers can still underwrite, but often with less focus and lower service intensity.

The second-order implication of the U.S. expansion is that Trisura may be building a distribution and licensing moat rather than just buying revenue. Full-state access and a broader surety footprint can reduce friction costs over time, but they also invite faster competitor response from better-capitalized incumbents if pricing stays attractive. In specialty insurance, the first phase of growth is usually easy; the risk is that expanded reach tempts management to chase premium volume just as claims frequency normalizes, which would show up first in the combined ratio before it hits book value.

The key contrarian angle is that the story is not about size, it's about persistently above-cost-of-capital underwriting plus reinvestment. Consensus may focus too much on book value growth as a backward-looking scorecard, when the real question is whether that growth is repeatable at scale without reserve deterioration. If Trisura can keep the combined ratio in the mid-80s for another 12-18 months, the multiple can rerate materially; if it drifts into the low 90s, the market will likely treat it as just another insurer with less room for error.

Key Decisions for Investors

• Long TSU.TO on pullbacks over the next 1-3 months; target a 12-month hold. Thesis: continued book value compounding should support further multiple expansion if underwriting stays sub-90 combined ratio. Risk: reserve creep or U.S. growth slowing before scale benefits show up.
• Buy TSU.TO Jan-2027 call spreads to express upside with defined premium at risk. Best setup if the market starts valuing book value growth more explicitly; avoid outright calls because insurer reratings can lag for quarters before a catalyst appears.
• Pair trade: long TSU.TO / short a diversified large-cap specialty insurer basket via CB over 6-12 months. The relative trade isolates growth + underwriting execution versus lower-growth incumbents; risk is that higher-quality large caps rerate on broad hard-market strength.
• Trim or avoid chasing after sharp post-earnings moves. The main downside scenario is not a catastrophic event but gradual multiple compression if combined ratio trends back toward 90-92% and investors stop paying for book value growth.